checkAd

     1044  0 Kommentare Toujeo® Receives Positive Opinion from the European Regulatory Authorities - Seite 2

    About Sanofi Diabetes
    Sanofi strives to help people manage the complex challenge of diabetes by delivering innovative, integrated and personalized solutions. Driven by valuable insights that come from listening to and engaging with people living with diabetes, the Company is forming partnerships to offer diagnostics, therapies, services, and devices including blood glucose monitoring systems. Sanofi markets injectable, inhaled and oral medications for people with type 1 or type 2 diabetes.

    About Sanofi
    Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Sanofi S.A.!
    Long
    84,68€
    Basispreis
    0,81
    Ask
    × 13,97
    Hebel
    Short
    98,33€
    Basispreis
    0,68
    Ask
    × 11,10
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    References

    1.      Steinstraesser A, Schmidt R, Bergmann K, et al. Diabetes, Obesity and Metabolism. 2014;16(9):873-6, DOI: 10.1111/dom.12283.
    2.      Becker RHA, Dahmen R, Bergmann K, et al. Diabetes Care. 2014:epub ahead of print, DOI: 10.2337/dc14-0006.
    3.      Shiramoto M, Eto T, Irie S, et al. Diabetes, Obesity and Metabolism. 2014:epub ahead of print, DOI: 10.1111/dom.12415.
    4.      Riddle MC, Bolli GB, Ziemen M, et al. Diabetes Care. 2014;37(10):2755-62, DOI: 10.2337/dc14-0991.
    5.      Yki-Järvinen H, Bergenstal R, Ziemen M, et al. Diabetes Care. 2014;37(12):3235-43, DOI: 10.2337/dc14-0990.
    6.      Bolli GB, Riddle MC, Bergenstal RM, et al. Diabetes, Obesity and Metabolism. 2015:epub ahead of print, DOI: 10.1111/dom.12438.
    7.      Home P, Bergenstal R, Riddle M, et al.  50th Annual Meeting of the European Association for the Study of Diabetes (EASD)2014.  Oral presentation abstract #148.
    8.      Matsuhisa M, Koyama M, Cheng X, et al.  50th Annual Meeting of the European Association for the Study of Diabetes (EASD)2014.  Poster abstract #975.
    9.      Terauchi Y, Koyama M, Cheng X, et al.  50th Annual Meeting of the European Association for the Study of Diabetes (EASD)2014.  Poster abstract #976.
    10.    Ritzel R, Roussel R, Bolli G, et al.  50th Annual Meeting of the European Association for the Study of Diabetes (EASD)2014.  Poster abstract #963.
    11.    Banegas JR, López-García E, Dallongeville J, et al. Eur Heart J. 2011;32(17):2143-52, DOI: 10.1093/eurheartj/ehr080.

    Seite 2 von 4


    Diskutieren Sie über die enthaltenen Werte


    GlobeNewswire
    0 Follower
    Autor folgen

    Verfasst von GlobeNewswire
    Toujeo® Receives Positive Opinion from the European Regulatory Authorities - Seite 2 Toujeo® Receives Positive Opinionfrom the European Regulatory Authorities Paris, France - February 27, 2015 - Sanofi announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued …

    Schreibe Deinen Kommentar

    Disclaimer